The Complete 2023 Landscape Review
An overview of the entire drug and trial landscape with a lens on therapeutic class, disease indication, targets, status and more, along with a look at the Deals and Companies data by deal type, company location and a recap of the regulatory announcements from 2023.
About the report
The analysis includes:
-
- The Drug Landscape – An analysis of all 1540+ assets in the TPD database, including the 513 new assets added in 2023, by therapeutic class, target and developer type.
- The Trial Landscape and Future of TPD’s – An analysis of the 2950+ clinical trials tracked on Beacon TPD and a deeper look into the new induced proximity data and how this affects the future of the space.
- The Commercial Landscape – A look at deals in the commercial space by type, value and the therapeutic class along with a overview of the company data using the brand new Deals and Companies database. Along with a review of the regulatory announcements by drug and type.
You may also be interested in...
Decoding the Bivalent Degrader Landscape – Novel PROTACs, Developer Trends, and Future Innovations
The 2023 TPD Landscape Review
2023 Oncolytic Viruses Landscape Review
Find out more
Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies, combined with the most accurate and comprehensive life sciences data, provide our customers with unparalleled visibility of the drug and trial landscape.
With Beacon, you can make drug development decisions with confidence. This is why 23 of the world’s top 25 drug developers trust us.
Speak with our team
Our dedicated account and research teams can help you with questions by showing you how this insight and data is collated on Beacon.
